Akari $2 Million Private Placement from Current Investors

 Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that it closed a private placement financing with existing investors, Akari Chairman Dr. Ray Prudo and Director Samir R. Patel, M.D., on December 29, 2023, resulting in gross proceeds of approximately $2 million.

In connection with the financing, Akari issued 947,868 unregistered American Depository Shares (“ADSs”), each representing 2,000 of the company’s ordinary shares, at a purchase price of $2.11 per ADS.

https://www.globenewswire.com/news-release/2024/01/02/2802629/0/en/Akari-Therapeutics-Announces-Existing-Investors-Support-the-Company-Through-a-2-Million-Private-Placement-Financing.html